uniQure N.V. (QURE)
QURE Stock Price Chart
Explore uniQure N.V. interactive price chart. Choose custom timeframes to analyze QURE price movements and trends.
QURE Company Profile
Discover essential business fundamentals and corporate details for uniQure N.V. (QURE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Feb 2014
Employees
221.00
Website
https://www.uniqure.comCEO
Matthew Kapusta
Description
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
QURE Financial Timeline
Browse a chronological timeline of uniQure N.V. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$0.83, while revenue estimate is $5.45m.
Earnings released on 5 May 2026
EPS came in at -$0.85 surpassing the estimated -$0.88 by +3.41%, while revenue for the quarter reached $3.56m , missing expectations by -31.56%.
Earnings released on 2 Mar 2026
EPS came in at -$0.56 surpassing the estimated -$0.93 by +39.78%, while revenue for the quarter reached $5.57m , beating expectations by +4.49%.
Earnings released on 10 Nov 2025
EPS came in at -$1.38 falling short of the estimated -$0.85 by -62.35%, while revenue for the quarter reached $3.70m , missing expectations by -23.60%.
Earnings released on 29 Jul 2025
EPS came in at -$0.69 surpassing the estimated -$0.89 by +22.47%, while revenue for the quarter reached $5.26m , beating expectations by +13.68%.
Earnings released on 9 May 2025
EPS came in at -$0.82 surpassing the estimated -$1.07 by +23.36%, while revenue for the quarter reached $1.57m , missing expectations by -73.43%.
Earnings released on 27 Feb 2025
EPS came in at -$1.50 falling short of the estimated -$0.60 by -150.00%, while revenue for the quarter reached $5.22m , missing expectations by -71.69%.
Earnings released on 5 Nov 2024
EPS came in at -$0.91 surpassing the estimated -$1.12 by +18.75%, while revenue for the quarter reached $2.29m , missing expectations by -87.52%.
Earnings released on 1 Aug 2024
EPS came in at -$1.16 surpassing the estimated -$1.24 by +6.45%, while revenue for the quarter reached $11.13m , beating expectations by +63.86%.
Earnings released on 7 May 2024
EPS came in at -$1.36 falling short of the estimated -$1.31 by -3.82%, while revenue for the quarter reached $8.49m , beating expectations by +36.20%.
Earnings released on 28 Feb 2024
EPS came in at -$1.53 surpassing the estimated -$1.54 by +0.65%, while revenue for the quarter reached $6.69m , beating expectations by +19.66%.
Earnings released on 7 Nov 2023
EPS came in at -$1.88 falling short of the estimated -$1.49 by -26.17%, while revenue for the quarter reached $1.41m , missing expectations by -76.97%.
Earnings released on 1 Aug 2023
EPS came in at -$1.44 falling short of the estimated $2.97 by -148.48%, while revenue for the quarter reached $2.42m , missing expectations by -98.83%.
Earnings released on 9 May 2023
EPS came in at -$1.63 falling short of the estimated -$1.02 by -59.80%, while revenue for the quarter reached $5.33m , missing expectations by -81.15%.
Earnings released on 27 Feb 2023
EPS came in at $0.15 surpassing the estimated -$0.89 by +116.85%, while revenue for the quarter reached $102.75m , beating expectations by +429.18%.
Earnings released on 2 Nov 2022
EPS came in at -$1.02 surpassing the estimated -$1.11 by +8.11%, while revenue for the quarter reached $1.45m , missing expectations by -58.40%.
Earnings released on 8 Aug 2022
EPS came in at -$0.84 surpassing the estimated -$0.96 by +12.50%, while revenue for the quarter reached $497.00k , missing expectations by -95.12%.
Earnings released on 2 May 2022
EPS came in at -$1.00 falling short of the estimated -$0.67 by -49.25%, while revenue for the quarter reached $1.79m , missing expectations by -89.85%.
Earnings released on 25 Feb 2022
EPS came in at $0.17 surpassing the estimated -$0.81 by +120.99%, while revenue for the quarter reached $57.69m , beating expectations by +436.84%.
Earnings released on 25 Oct 2021
EPS came in at -$0.79 surpassing the estimated -$1.00 by +21.00%, while revenue for the quarter reached $1.99m , missing expectations by -21.07%.
Earnings released on 26 Jul 2021
EPS came in at $8.51 surpassing the estimated $2.96 by +187.50%, while revenue for the quarter reached $463.87m , beating expectations by +18.31k%.
QURE Stock Performance
Access detailed QURE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
